Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.46M Buy
12,329
+703
+6% +$241K 0.63% 39
2026
Q1
$4.09M Buy
11,626
+954
+9% +$340K 0.7% 35
2025
Q4
$3.49M Buy
10,672
+787
+8% +$250K 0.59% 39
2025
Q3
$2.79M Sell
9,885
-25
-0.3% -$7.25K 0.48% 53
2025
Q2
$2.77M Buy
9,910
+368
+4% +$104K 0.53% 45
2025
Q1
$2.97M Buy
9,542
+184
+2% +$54.3K 0.5% 47
2024
Q4
$2.44M Buy
+9,358
New +$2.78M 0.53% 46

Other funds holding AMGN

Huntleigh Advisors's AMGN Position: Q2 2026 in Review

Huntleigh Advisors increased its Amgen (AMGN) stake by 6% in Q2 2026, buying an estimated $241K and bringing the position to 12,329 shares worth $4.46M. The position accounts for 0.63% of the portfolio, ranked #39.

Huntleigh Advisors first reported a position in AMGN in Q4 2024 and has held it in 7 quarters since. 3,164 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Huntleigh Advisors held 12,329 shares of Amgen worth $4.46M as of Q2 2026.
  • Huntleigh Advisors bought 703 Amgen shares in Q2 2026, an estimated $241K.
  • Amgen made up 0.63% of Huntleigh Advisors's portfolio in Q2 2026, its #39 holding.
  • Huntleigh Advisors first reported a position in Amgen in Q4 2024 and has held it in 7 quarters since.
  • 3,164 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Huntleigh Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.